Change in baseline trough FEV1 · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Hospital admissions · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium probably leads to lower hospital admissions (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Quality of life ( · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
Exacerbations · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower patients with one or more exacerbations compared with ipratropium (high certainty).
1 finding from 1 review
Treatment withdrawal · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower withdrawals compared with ipratropium (high certainty).
1 finding from 1 review
QoL · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in quality of life (SGRQ) Scale 0 to 100, where 100 represents worst… compared with placebo (high certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium leads to higher number of patients with a clinically significant improvement (≥ 4… compared with placebo (high certainty).
1 finding from 1 review
Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ) · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium leads to lower number of patients with a clinically significant worsening (≥ 4… compared with placebo (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium leads to lower number of patients with one or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in number of patients with one or more exacerbations requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Hospital admissions · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in number of patients with one or more hospitalisations for any cause compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
1 finding from 1 review
Hospitalisations, number of participants with 1 or more exacerbations · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
Tiotropium probably leads to lower patients with 1 or more exacerbations compared with long‐acting beta‐agonists (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
1 finding from 1 review
no estimate extracted
6 participants
Low
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with tiotropium alone (moderate certainty).
1 finding from 1 review